⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Figure S2 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer

Jamie M. Sperger Kyle T. Helzer Charlotte N. Stahlfeld Dawei Jiang Anupama Singh Katherine R. Kaufmann David J. Niles Erika Héninger Nicholas R. Rydzewski Liguo Wang Liewei Wang Rendong Yang Yanan Ren Jonathan W. Engle Peng Huang Christos E. Kyriakopoulos Susan F. Slovin Howard R. Soule Shuang G. Zhao Manish Kohli Scott T. Tagawa Weibo Cai Scott M. Dehm Joshua M. Lang

View at Publisher

Ask AI

Bookmark

Share

Key Points

Capture efficiency varies across designated Trop-2 expressing cell lines, demonstrating differential surface marker isolation in resistant prostate cancer.
Assessment of capture efficiency profiles was conducted across distinct Trop-2 expressing cell lines, tracking recovery in treatment resistant prostate cancer.
Preclinical cell lines support therapeutic targeting of Trop-2 in resistant prostate cancer, though in vivo validation and clinical efficacy trials are needed.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

In vitro analysis reveals capture efficiency across Trop-2 expressing cell lines, highlighting therapeutic targeting in resistant prostate cancer.

Abstract

Figure S2. Capture Efficiency of Trop-2 Expressing Cell Lines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sperger et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522d9e https://doi.org/10.1158/1078-0432.27030460.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S3 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer2024
2Figure S1 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer2024
3Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer2024
4Data from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer2024
5Abstract 7225: TROP2 expression is abundant in primary and recurrent prostate cancerOriginal Research · 2026

More related papers

Supplementary figure 16 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer2024
Supplementary figure 16 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer2024
Supplementary figure 15 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer2024